Table 1. Subject characteristics (n = 164).

Age, mean years, SD [range]	45.1 ± 10.2 [20–71]
Age 20–40 years, n (%)	43 (26.2%)
Age 41–60 years, n (%)	112 (68.3%
Age > 60 years, n (%)	9 (5.5%)
Male, n (%)	115 (70.1%)
BMI, mean, SD [range]	27.7 ± 6.5 [18.8–53.8]
BMI <18.5 underweight, n (%)	0 (0%)
BMI 18.5–25 normal, n (%)	65 (39.6%)
BMI 25–30 overweight, n (%)	55 (33.6%)
BMI > 30 obese, n (%)	44 (26.8%)
Race
Caucasian, n (%)	71 (43.3%)
Black, n (%)	93 (56.7%)
Smoking status
Never, n (%)	30 (18.4%)
Current, n (%)	96 (58.9%)
Former, n (%)	37 (22.7%)
Pack years, mean, SD [range]	17.3 ± 17.6 [0–105]
Viral load, median copies/mL [IQR]	49 [630]
CD4 count, median cells/microL [IQR]	561.5 [369]
Overall Antiretroviral therapy (yes), n (%)	132 (90%)
TDF use, n (%)	109 (82.6%)
Oral steroid use last 12 months (yes), n (%)	9 (5.7%)
Estrogen/progesterone use, n (%)	3 (1.8%)
Testosterone use, n (%)	1 (0.6%)
FEV1 mean percent predicted, SD	94.2 ± 17.9
Obstruction
At Risk, n (%)	136 (82.93%)
GOLD I, n (%)	14 (8.54%)
GOLD II, n (%)	12 (7.31%)
GOLD III, n (%)	2 (1.22%)
Attenuation area %, median [IQR]	6.9 [11.7]
Mean HU value across T4, T7, T10, SD	212.8 ± 46.4

SD = standard deviation, IQR = interquartile range, FEV1 = forced expiratory volume in the first second, Emphysema = <-950 HU on chest ct